SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zeneca Group plc (NYSE ticker ZEN) -- Ignore unavailable to you. Want to Upgrade?


To: JF2155 who wrote (37)9/2/1998 6:49:00 PM
From: Anthony Wong  Read Replies (1) | Respond to of 75
 
Jim, the Bloomberg article wasn't that positive about Tamoxifen (side effects concerns, the drug being off-patent in some countries etc.), and it was not mentioned how much additional revenue this would bring. Even Eli Lilly, which was supposed to benefit from the news (because of Evista), lost all its gains today. Genentech fared better.

A more updated version of the Bloomberg report:
news.com



To: JF2155 who wrote (37)9/2/1998 7:24:00 PM
From: Anthony Wong  Respond to of 75
 
Jim, CNBC reported that an analyst from Hambrecht & Quist said that if the FDA does give final approval to Tamoxifen, it may add an additional 400 - 500 million dollar revenue to ZEN, depending how much marketing muscle ZEN puts behind the drug.